Trial Begins Dosing of ‘Off-the-shelf’ CAR T-cell Therapy for Multiple Myeloma

Home / Blog / Trial Begins Dosing of ‘Off-the-shelf’ CAR T-cell Therapy for Multiple Myeloma
Trial Begins Dosing of ‘Off-the-shelf’ CAR T-cell Therapy for Multiple Myeloma
September 03, 2020September 3, 2020
0

The first patient has been dosed in a Phase 1/2a trial investigating Precision BioSciences‘ new CAR T-cell therapy candidate, PBCAR269A, for people with relapsed or refractory multiple myeloma. The dose-escalation trial (NCT04171843) is expected to recruit 48 participants at five clinical sites in the U.S. Enrollment is now active at City of Hope, in California, and at Columbia University Irving Medical Center, in New York. More information on enrollment is available here. “There remains significant unmet…

You must be logged in to read/download the full post.

The post Trial Begins Dosing of ‘Off-the-shelf’ CAR T-cell Therapy for Multiple Myeloma appeared first on BioNewsFeeds.